Use este identificador para citar ou linkar para este item:
http://sgc.anlis.gob.ar/handle/123456789/2256
Título: | OMV-based vaccine formulations against Shiga toxin producing Escherichia coli strains are both protective in mice and immunogenic in calves | Autor(es): | Fingermann, Matías Ávila, Lucía De Marco, María Vázquez, Luciana Di Biase, Darío Nicolás Müller, Andrea Verónica Lescano, Mirta Dokmetjian, Christian Fernández Castillo, Sonsire Pérez Quiñoy, José Luis |
Palavras-chave: | Bovinos;Síndrome Hemolítico-Urémico;Toxina Shiga;Vaccinia;Zoonosis | Data do documento: | 12-Jul-2018 | Jornal: | Human Vaccines & Immunotherapeutics | Resumo: | Strains of Shiga toxin-producing Escherichia coli (STEC) can cause the severe Hemolytic Uremic Syndrome (HUS). Shiga toxins are protein toxins that bind and kill microvascular cells, damaging vital organs. No specific therapeutics or vaccines have been licensed for use in humans yet. The most common route of infection is by consumption of dairy or farm products contaminated with STEC. Domestic cattle colonized by STEC strains represent the main reservoir, and thus a source of contamination. Outer Membrane Vesicles (OMV) obtained after detergent treatment of gram-negative bacteria have been used over the past decades for producing many licensed vaccines. These nanoparticles are not only multi-antigenic in nature but also potent immunopotentiators and immunomodulators. Formulations based on chemical-inactivated OMV (OMVi) obtained from a virulent STEC strain (O157:H7 serotype) were found to protect against pathogenicity in a murine model and to be immunogenic in calves. These initial studies suggest that STEC-derived OMV has a potential for the formulation of both human and veterinary vaccines. |
Descrição: | Fil: Fingermann, Matias. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Producción de Biológicos; Argentina. Fil: Avila, Lucía. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Producción de Biológicos; Argentina. Fil: De Marco, Maria Belén. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Producción de Biológicos; Argentina. Fil: Vázquez, Luciana. ANLIS Dr.C.G.Malbrán. Unidad Operativa Centro de Contención Biológica; Argentina. Fil: Di Biase, Darío Nicolás. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Producción de Biológicos; Argentina. Fil: Müller, Andrea Verónica. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Producción de Biológicos; Argentina. Fil: Lescano, Mirta. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Producción de Biológicos; Argentina. Fil: Dokmetjian, José Christian. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Producción de Biológicos; Argentina. Fil: Fernández Castillo, Sonsire. Instituto Finlay, La Habana; Cuba. Fil: Pérez Quiñoy, José Luis. Instituto Finlay, La Habana; Cuba. |
URI: | http://sgc.anlis.gob.ar/handle/123456789/2256 | ISSN: | 2164-554X | DOI: | 10.1080/21645515.2018.1490381 | Direitos: | Open Access Creative Commons Attribution 4.0 International License |
Aparece nas Coleções: | Publicaciones INPB |
Arquivos neste item:
Arquivo | Descrição | Tamanho | Formato | |
---|---|---|---|---|
HumanVaccines&Immunotherapeutics_2018_14_9_p2208-p2213.pdf | 901.1 kB | Adobe PDF | Ver/Aberto |
Visualização de página
30
Checado em 01/05/2024
Download(s)
4
Checado em 01/05/2024
Google ScholarTM
Checar
Altmetric
Altmetric
Este item está licenciada sob uma Licença Creative Commons